DelveInsight’s “Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Chronic Rhinosinusitis with Nasal Polyps pipeline landscape. It covers the Chronic Rhinosinusitis with Nasal Polyps Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Chronic Rhinosinusitis with Nasal Polyps Pipeline? @ https://www.delveinsight.com/sample-request/chronic-rhinosinusitis-with-nasal-polyps-pipeline-insight

Key Takeaways from the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report

• On June 10, 2026- AstraZeneca initiated a phase IIIb study is to describe changes from baseline in (1) participant-reported nasal congestion as evaluated by the nasal congestion score (NCS) and (2) participant-reported sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) following initiation of tezepelumab treatment.
• On June 03, 2026- Eli Lilly and Company conducted a phase 3 study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
• On June 02, 2026- Sanofi announced a Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older.
• DelveInsight’s Chronic Rhinosinusitis with Nasal Polyps Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Chronic Rhinosinusitis with Nasal Polyps treatment.
• The leading Chronic Rhinosinusitis with Nasal Polyps Companies such as Keymed Biosciences Co. Ltd, GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co Ltd and others.
• Promising Chronic Rhinosinusitis with Nasal Polyps Therapies such as Tezepelumab, Verekitug (UPB-101), GR1802, Dupilumab SAR231893, Mepolizumab, lunsekimig, Itepekimab (SAR440340), CM310, Omalizumab and others.

Want to know which companies are leading innovation in Chronic Rhinosinusitis with Nasal Polyps? @ Chronic Rhinosinusitis with Nasal Polyps Clinical Trials Assessment

The Chronic Rhinosinusitis with Nasal Polyps Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Chronic Rhinosinusitis with Nasal Polyps Pipeline Report also highlights the unmet needs with respect to the Chronic Rhinosinusitis with Nasal Polyps.

Chronic Rhinosinusitis with Nasal Polyps Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition affecting the nasal passages and sinuses, characterized by the growth of benign polyps. These polyps, which are soft, painless, and non-cancerous, arise from the mucous membranes and can obstruct the nasal airways, leading to significant breathing difficulties. Patients often experience symptoms such as nasal congestion, a reduced sense of smell, facial pain or pressure, and nasal discharge. The condition is distinct from other forms of chronic rhinosinusitis due to the presence of these polyps, which play a critical role in the chronic nature and severity of the disease.

Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs Profile

• GSK3511294: GlaxoSmithKline

GSK3511294 (depemokimab) is a novel investigational treatment being studied for chronic rhinosinusitis with nasal polyps (CRSwNP). Depemokimab is thought to work by inhibiting interleukin-5 (IL-5), a key cytokine involved in the type 2 inflammatory response that drives eosinophilic inflammation in CRSwNP. Blocking IL-5 may help reduce polyp size and improve symptoms. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Chronic rhinosinusitis with nasal polyps.

• CM326: Keymed Biosciences Co.Ltd

CM326 is a monoclonal antibody being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The rationale for targeting thymic stromal lymphopoietin (TSLP) with CM326 is based on its role in the pathogenesis of CRSwNP. TSLP is a key cytokine involved in the initiation and maintenance of type 2 inflammatory responses, which are characteristic of CRSwNP. Currently, the drug is in the Phase II stage of development to treat Chronic rhinosinusitis with nasal polyps.

If you’re tracking ongoing Chronic Rhinosinusitis with Nasal Polyps Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Chronic Rhinosinusitis with Nasal Polyps Treatment Drugs

The Chronic Rhinosinusitis with Nasal Polyps Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Rhinosinusitis with Nasal Polyps with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Rhinosinusitis with Nasal Polyps Treatment.
• Chronic Rhinosinusitis with Nasal Polyps Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Rhinosinusitis with Nasal Polyps Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Rhinosinusitis with Nasal Polyps market.

Chronic Rhinosinusitis with Nasal Polyps Companies

Keymed Biosciences Co., Ltd., GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co Ltd and others

Chronic Rhinosinusitis with Nasal Polyps Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chronic Rhinosinusitis with Nasal Polyps Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report @ Chronic Rhinosinusitis with Nasal Polyps Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report

• Coverage- Global
• Chronic Rhinosinusitis with Nasal Polyps Companies- Keymed Biosciences Co. Ltd, GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co Ltd and others.
• Chronic Rhinosinusitis with Nasal Polyps Therapies- Tezepelumab, Verekitug (UPB-101), GR1802, Dupilumab SAR231893, Mepolizumab, lunsekimig, Itepekimab (SAR440340), CM310, Omalizumab and others.
• Chronic Rhinosinusitis with Nasal Polyps Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Rhinosinusitis with Nasal Polyps Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Chronic Rhinosinusitis with Nasal Polyps Treatment landscape in this detailed analysis @ Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Chronic Rhinosinusitis with Nasal Polyps: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Rhinosinusitis with Nasal Polyps – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. GSK3511294: GlaxoSmithKline
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CM310: Keymed Biosciences
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Rhinosinusitis with Nasal Polyps Key Companies
21. Chronic Rhinosinusitis with Nasal Polyps Key Products
22. Chronic Rhinosinusitis with Nasal Polyps- Unmet Needs
23. Chronic Rhinosinusitis with Nasal Polyps- Market Drivers and Barriers
24. Chronic Rhinosinusitis with Nasal Polyps- Future Perspectives and Conclusion
25. Chronic Rhinosinusitis with Nasal Polyps Analyst Views
26. Chronic Rhinosinusitis with Nasal Polyps Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-pipeline-insight